🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

113 results for “SUBSTANCE” Clear

  1. Lorazepam

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 small molecule terminated

    1 trial

  2. MOVIPREP, MaaT033, MOVIPREP Orange, poudre pour solution buvable, Placebo is an inert coated capsule with no microbiota (active substance) inside. It is composed of a mix of coloring agents and partially pre-gelatinized corn starch in Hydroxypropyl methylcellulose capsule.

    Pari Pharma GmbH

    AXIAL SPONDYLOARTHRITIS

    phase 2 small molecule active

    1 trial

  3. Matching Placebo tablets without active substance, BIIB122

    Biogen

    Parkinson's Disease

    phase 2 small molecule active

    1 trial

  4. Matching placebo tablets without active substance, BI 706321, BI 706321, BI 706321, STELARA 130 mg concentrate for solution for infusion, STELARA 90 mg solution for injection in pre-filled pen

    Boehringer Ingelheim

    Crohn`s Disease (CD)

    phase 2 small molecule active

    1 trial

  5. Mindfulness Based Relapse Prevention

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

  6. Monitoring and Feedback Intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  7. Navigating my Journey program

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 other completed

    1 trial

  8. Normix 200 mg compresse rivestite con film, The placebo is a film-coated oral tablet designed to be comparable in appearance, administration, and handling to the investigational medicinal product (rifaximin 200 mg film-coated tablets), while containing no active pharmaceutical ingredient. The placebo consists exclusively of commonly used pharmaceutical excipients with established safety profiles and is administered solely to maintain blinding in the clinical trial.

    Fondazione Telethon ETS

    substance use disorder

    phase 2 small molecule active

    1 trial

  9. PEMBROLIZUMAB , EIK1001 solution for injection 1.0 mg/mL free base equivalent, Inactive control which is identical in appearance and composition as EIK1001 drug product except for the lack of EIK1001 drug substance

    Eikon Therapeutics

    Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  10. Placebo is identical with the test product and just does not contain active substance.

    Lacuna Pharma Pty Ltd

    Prurigo Nodularis

    phase 2 small molecule active

    1 trial

  11. Recovery by Choice

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 other completed

    1 trial

  12. Rotigotine Transdermal System [Neupro]

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 small molecule active

    1 trial

  13. SUL-238, Identical to test product except without active substance

    Sana Biotechnology

    Parkinson’s Disease

    phase 2 small molecule active

    1 trial

  14. Standard Cognitive Behavioral Treatment

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 other completed

    1 trial

  15. Standard Treatment As Usual (TAU)

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  16. The placebo used the same excipients as that used in IMP without active drug substance. The placebo was developed as film-coated tablet same in size and appearance to the IMP., BRENSOCATIB, BRENSOCATIB

    Insmed Limited

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  17. atomoxetine

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 small molecule completed

    1 trial

  18. mirtazapine

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 small molecule completed

    1 trial

  19. A Phase I, open-label study in healthy adults comparing the availability in the body of the active substance lidocaine following administration of 2% and 4% lidocaine gel into the urethra

    Lacuna Pharma Pty Ltd

    bioavailability trial with healthy participants, therapeutic indication not studied

    phase 1 other active

    1 trial

  20. A study to compare how different substances (caffeine, warfarin, omeprazole, metoprolol, and midazolam) are handled by the body of healthy people and people with liver cirrhosis

    Boehringer Ingelheim

    1. Patients with compensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh A 2. Patients with decompensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh B

    phase 1 other active

    1 trial

  21. CS-1103

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 1 small molecule completed

    1 trial

  22. Methylphenidate

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorder

    phase 1 small molecule active

    1 trial

  23. Mindful Awareness in Body-oriented Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorder

    phase 1 other completed

    1 trial

  24. Motivational Network Intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use

    phase 1 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources